Advicenne SA (FR:ALDVI)
:ALDVI
Want to see FR:ALDVI full AI Analyst Report?
Top Page
Advicenne SA
(ALDVI)
Select Model
Select Model
Rating:38Underperform
Price Target:
€1.00
▼(-41.86% Downside)
Action:DowngradedDate:05/05/26
The score is held down primarily by very weak financial performance (persistent losses, cash burn, and negative equity) and a bearish technical trend (below all major moving averages with negative MACD and oversold momentum). Valuation is also unattractive due to negative earnings (negative P/E) and no dividend support.
Positive Factors
Specialized renal product
Advicenne’s core asset is a proprietary prolonged‑release potassium citrate (Sibnayal) for rare renal diseases. A differentiated, approved formulation in a niche indication creates durable clinical demand, higher switching costs and a defensible commercial franchise once uptake and reimbursement scale.
Negative Factors
Negative equity / fragile balance sheet
Persistently negative equity signals structural capital deficits, restricting financing alternatives and increasing dilution or insolvency risk. It impairs the company’s ability to absorb shocks, limits covenant‑free borrowing and constrains strategic optionality over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized renal product
Advicenne’s core asset is a proprietary prolonged‑release potassium citrate (Sibnayal) for rare renal diseases. A differentiated, approved formulation in a niche indication creates durable clinical demand, higher switching costs and a defensible commercial franchise once uptake and reimbursement scale.
Read all positive factors
Advicenne SA (ALDVI) vs. iShares MSCI France ETF (EWQ)
Market Cap
€17.91M
Dividend YieldN/A
Average Volume (3M)26.23K
Price to Earnings (P/E)―
Beta (1Y)0.41
Revenue Growth20.77%
EPS Growth-36.61%
CountryFR
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding14,609,619
10 Day Avg. Volume23,481
30 Day Avg. Volume26,231
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.96
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.22
Revenue Forecast (FY)€8.04M
Advicenne SA Business Overview & Revenue Model
Company Description
Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advic...
How the Company Makes Money
Advicenne makes money primarily by selling its specialty pharmaceutical product(s), with revenues generated from the commercialization of Sibnayal® in markets where it has obtained regulatory approval and reimbursement. The revenue model is mainly...
Advicenne SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.58M | 5.79M | 4.97M | 4.46M | 2.40M | 2.69M |
| Gross Profit | -2.30M | 1.91M | -1.18M | -6.31M | 1.28M | 1.72M |
| EBITDA | 2.87M | -3.73M | 1.30M | -6.24M | -9.87M | -12.04M |
| Net Income | -5.89M | -9.53M | -6.46M | -7.03M | -11.47M | -12.43M |
Balance Sheet | ||||||
| Total Assets | 6.73M | 7.14M | 9.51M | 12.41M | 14.26M | 18.88M |
| Cash, Cash Equivalents and Short-Term Investments | 515.00K | 1.34M | 3.25M | 5.25M | 8.32M | 12.69M |
| Total Debt | 18.67M | 19.00M | 18.19M | 18.32M | 18.75M | 12.54M |
| Total Liabilities | 30.73M | 33.51M | 28.58M | 24.38M | 24.88M | 18.57M |
| Stockholders Equity | -24.00M | -26.37M | -19.07M | -11.97M | -10.50M | 309.00K |
Cash Flow | ||||||
| Free Cash Flow | 1.83M | -4.11M | -853.00K | -7.27M | -9.26M | -12.82M |
| Operating Cash Flow | 1.89M | -3.73M | -762.00K | -5.99M | -9.15M | -12.53M |
| Investing Cash Flow | -73.00K | -403.00K | -108.00K | -1.32M | -2.00K | -395.00K |
| Financing Cash Flow | -532.00K | 2.23M | -1.13M | 4.23M | 4.78M | 8.85M |
Advicenne SA Technical Analysis
Negative
1.72
Price Trends
1.84
Negative
1.80
Negative
1.62
Negative
Market Momentum
-0.14
Positive
27.63
Positive
15.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALDVI, the sentiment is Negative. The current price of 1.72 is above the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.84, and above the 200-day MA of 1.62, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 27.63 is Positive, neither overbought nor oversold. The STOCH value of 15.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALDVI.
Advicenne SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | €120.13M | -10.55 | -85.59% | ― | -10.72% | -21.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | €199.46M | -1.89 | -40.00% | ― | ― | -5.60% | |
45 Neutral | €19.97M | -0.97 | 51.23% | ― | -99.93% | 44.53% | |
38 Underperform | €17.91M | -1.37 | ― | ― | 20.77% | -36.61% | |
37 Underperform | €98.08K | ― | ― | ― | -80.66% | 99.99% |
* Healthcare Sector Average
FR:ALDVI
Advicenne SA
1.23
-0.51
-29.31%
FR:SIGHT
GenSight Biologics SA
0.09
-0.14
-62.88%
FR:GNRO
GeNeuro SA
0.03
-0.04
-53.85%
FR:ABNX
ABIONYX Pharma SA
3.41
2.20
182.28%
FR:ALSEN
Sensorion SAS
0.39
-0.06
-12.64%
FR:ALNEV
Neovacs SA
0.01
-14.09
-99.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.